Entero Therapeutics
Boca Raton
About Entero Therapeutics
Entero Therapeutics is a late clinical-stage biopharmaceutical company that develops targeted, non-systemic therapies for gastrointestinal (GI) diseases. The Company’s programs target key unmet needs in gastrointestinal health. These include latiglutenase, an advanced oral treatment for celiac disease; capeserod, a selective drug for conditions like gastroparesis; and adrulipase, an enzyme to help cystic fibrosis and chronic pancreatitis patients digest fats and nutrients.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $71.6M
- Funding stage: IPO
- Last round: Post-IPO Equity (Aug 2025)
- Ticker: nasdaq:FWBI
- Website: enterothera.com
- Phone: (561) 589-7020
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/entero-therapeutics-94923 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.